[go: up one dir, main page]

MA45504A1 - Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives - Google Patents

Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Info

Publication number
MA45504A1
MA45504A1 MA45504A MA45504A MA45504A1 MA 45504 A1 MA45504 A1 MA 45504A1 MA 45504 A MA45504 A MA 45504A MA 45504 A MA45504 A MA 45504A MA 45504 A1 MA45504 A1 MA 45504A1
Authority
MA
Morocco
Prior art keywords
myeloproliferative
telomerase inhibitors
treatment
myeloproliferative disorders
neoplasias
Prior art date
Application number
MA45504A
Other languages
English (en)
Other versions
MA45504B1 (fr
Inventor
Monic Stuart
Stephen Kelsey
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MA45504A1 publication Critical patent/MA45504A1/fr
Publication of MA45504B1 publication Critical patent/MA45504B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés pour réduire la prolifération de cellules progénitrices néoplasiques et soulager des symptômes associés chez des individus diagnostiqués avec ou suspectés d'avoir des troubles myéloprolifératifs, tels que la thrombocytémie essentielle (te). La présente invention concerne en outre des procédés d'utilisation d'inhibiteurs de télomérase pour maintenir les numérations plaquettaires sanguines dans des plages relativement normales dans le sang d'individus diagnostiqués avec ou suspectés d'avoir des troubles myéloprolifératifs, tels que te.
MA45504A 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives MA45504B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Publications (2)

Publication Number Publication Date
MA45504A1 true MA45504A1 (fr) 2020-05-29
MA45504B1 MA45504B1 (fr) 2021-10-29

Family

ID=50883867

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45504A MA45504B1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
MA38193A MA38193B1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA38193A MA38193B1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Country Status (37)

Country Link
EP (3) EP3456333B8 (fr)
JP (6) JP6433911B2 (fr)
KR (4) KR102294819B1 (fr)
CN (2) CN104936602B (fr)
AP (1) AP2015008504A0 (fr)
AU (4) AU2013356533B2 (fr)
BR (1) BR112015013260A2 (fr)
CA (2) CA2892907C (fr)
CL (2) CL2015001530A1 (fr)
CY (2) CY1122169T1 (fr)
DK (3) DK3646876T3 (fr)
EA (1) EA032973B1 (fr)
ES (3) ES2982897T3 (fr)
FI (2) FI3646876T3 (fr)
FR (1) FR25C1016I1 (fr)
HK (1) HK1210940A1 (fr)
HR (3) HRP20191784T1 (fr)
HU (4) HUE045098T2 (fr)
IL (3) IL317233A (fr)
LT (4) LT3456333T (fr)
MA (2) MA45504B1 (fr)
ME (1) ME03538B (fr)
MX (3) MX372753B (fr)
MY (2) MY180634A (fr)
NL (1) NL301326I2 (fr)
NZ (1) NZ708920A (fr)
PH (2) PH12019501008A1 (fr)
PL (3) PL3456333T3 (fr)
PT (3) PT3646876T (fr)
RS (2) RS60401B1 (fr)
SG (3) SG10202103341SA (fr)
SI (3) SI2928477T1 (fr)
SM (2) SMT201900567T1 (fr)
TN (1) TN2015000249A1 (fr)
UA (3) UA117116C2 (fr)
WO (1) WO2014088785A1 (fr)
ZA (3) ZA201504124B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485717B2 (en) 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SI3030227T1 (sl) 2013-08-07 2020-08-31 Incyte Corporation Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1
DK3065828T3 (en) * 2013-11-06 2019-04-15 Mayo Found Medical Education & Res METHODS AND MATERIALS FOR TREATING HEMATOLOGICAL MALIGNITIES
RS60645B1 (sr) 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
EP3318276A1 (fr) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
US12171778B2 (en) * 2017-07-28 2024-12-24 Geron Corporation Methods of treating myelodysplastic syndrome
IL308399B2 (en) * 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
MX2020012503A (es) * 2018-05-25 2021-08-11 Kartos Therapeutics Inc Métodos de tratamiento de neoplasias mieloproliferativas.
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
US12201645B2 (en) 2018-11-29 2025-01-21 Geron Corporation Methods of treating myelodysplastic syndrome
MX2022005354A (es) 2019-11-04 2022-10-21 Geron Corp Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas.
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
CA3181682A1 (fr) * 2020-07-17 2022-01-20 Anil Kapur Compositions inihibitrices de telomerase sous-cutanees et leurs methodes d'utilisation
US20240108734A1 (en) * 2021-01-22 2024-04-04 The Regents Of The University Of California Methods for treating and ameliorating cancer
WO2024259369A1 (fr) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions ciblant des cellules géantes dans des troubles sanguins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP2007525414A (ja) * 2003-01-31 2007-09-06 ジェシー エル エス オウ スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
ES2775525T3 (es) 2003-09-09 2020-07-27 Geron Corp Oligonucleótidos modificados para la inhibición de la telomerasa
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
US7485717B2 (en) 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (fr) * 2005-04-15 2006-10-26 Geron Corporation Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
EP1876893B1 (fr) 2005-04-15 2012-04-11 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PT2101789E (pt) * 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
AU2020267142A1 (en) 2020-12-03
CA3188494A1 (fr) 2014-06-12
CA2892907A1 (fr) 2014-06-12
TN2015000249A1 (en) 2016-10-03
MX2020003276A (es) 2020-07-20
MX372753B (es) 2020-06-26
UA126015C2 (uk) 2022-08-03
PT3456333T (pt) 2020-06-01
IL280144B1 (en) 2025-01-01
EP3456333A1 (fr) 2019-03-20
MY200076A (en) 2023-12-06
NZ748134A (en) 2020-10-30
FIC20250019I1 (fi) 2025-05-07
SI3456333T1 (sl) 2020-10-30
HUS2500019I1 (hu) 2025-05-28
SG10201802926XA (en) 2018-05-30
NZ708920A (en) 2020-08-28
CY1122169T1 (el) 2020-11-25
JP2018035196A (ja) 2018-03-08
JP2016504307A (ja) 2016-02-12
AU2013356533B2 (en) 2018-09-27
HRP20191784T1 (hr) 2019-12-27
SMT201900567T1 (it) 2019-11-13
HK1212226A1 (en) 2016-06-10
LT2928477T (lt) 2019-10-10
JP2025109842A (ja) 2025-07-25
JP2022179684A (ja) 2022-12-02
AU2020267142B2 (en) 2024-05-16
SI3646876T1 (sl) 2024-07-31
RS59363B1 (sr) 2019-11-29
AU2013356533A1 (en) 2014-06-12
MA38193A1 (fr) 2017-12-29
PT2928477T (pt) 2019-10-25
PH12019501008A1 (en) 2022-11-14
JP2022050537A (ja) 2022-03-30
CL2015001530A1 (es) 2016-03-28
HUE049858T2 (hu) 2020-11-30
IL280144B2 (en) 2025-05-01
PL3646876T3 (pl) 2024-07-22
CN104936602B (zh) 2020-07-17
MX2022015437A (es) 2023-01-11
SG11201504383TA (en) 2015-07-30
UA128370C2 (uk) 2024-06-26
SG10202103341SA (en) 2021-05-28
IL239266A0 (en) 2015-07-30
JP6998191B2 (ja) 2022-02-04
CY1123206T1 (el) 2021-10-29
JP7288098B2 (ja) 2023-06-06
JP6433911B2 (ja) 2018-12-05
RS60401B1 (sr) 2020-07-31
EP3456333B1 (fr) 2020-04-01
WO2014088785A8 (fr) 2015-07-16
NL301326I2 (nl) 2025-07-31
CN104936602A (zh) 2015-09-23
EA032973B1 (ru) 2019-08-30
EP2928477B1 (fr) 2019-07-24
WO2014088785A1 (fr) 2014-06-12
FR25C1016I1 (fr) 2025-06-20
JP2020041001A (ja) 2020-03-19
PH12015501282B1 (en) 2015-08-24
HUE066402T2 (hu) 2024-07-28
LT3646876T (lt) 2024-05-10
LTPA2025517I1 (fr) 2025-05-26
DK2928477T3 (da) 2019-10-07
EP3646876A1 (fr) 2020-05-06
HRP20240624T1 (hr) 2024-08-02
AU2020267142C1 (en) 2024-08-08
PH12015501282A1 (en) 2015-08-24
DK3456333T3 (da) 2020-05-18
CL2017002156A1 (es) 2018-05-04
CN111617252A (zh) 2020-09-04
KR20150091130A (ko) 2015-08-07
AU2018282364A1 (en) 2019-05-23
SMT202000328T1 (it) 2020-07-08
ES2982897T3 (es) 2024-10-18
CA2892907C (fr) 2023-03-21
KR102294819B1 (ko) 2021-09-01
ZA202212327B (en) 2025-03-26
MY180634A (en) 2020-12-03
ZA201504124B (en) 2017-05-31
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
BR112015013260A2 (pt) 2018-02-06
MA38193B1 (fr) 2018-12-31
KR20230028590A (ko) 2023-02-28
SI2928477T1 (sl) 2019-11-29
EP2928477A4 (fr) 2016-09-21
IL280144A (en) 2021-03-01
DK3646876T3 (da) 2024-05-06
IL317233A (en) 2025-01-01
IL239266B (en) 2019-11-28
ES2744790T3 (es) 2020-02-26
KR20250114449A (ko) 2025-07-29
HK1210940A1 (zh) 2016-05-13
EP3646876B1 (fr) 2024-02-14
EP2928477A1 (fr) 2015-10-14
EP3456333B8 (fr) 2020-05-13
UA117116C2 (uk) 2018-06-25
EA201590878A1 (ru) 2016-04-29
PL3456333T3 (pl) 2020-09-21
FI3646876T3 (fi) 2024-05-14
ME03538B (fr) 2020-07-20
ES2789176T3 (es) 2020-10-26
MA45504B1 (fr) 2021-10-29
PT3646876T (pt) 2024-05-15
AP2015008504A0 (en) 2015-06-30
PL2928477T3 (pl) 2020-03-31
ZA202108991B (en) 2023-05-31
MX2015007169A (es) 2016-03-31
AU2024203138A1 (en) 2024-07-25
KR102662590B1 (ko) 2024-05-03
LT3456333T (lt) 2020-06-25
KR20210107906A (ko) 2021-09-01

Similar Documents

Publication Publication Date Title
MA45504A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
WO2014153115A3 (fr) Compositions et procédés de reprogrammation de lignées de cellules souches hématopoïétiques
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
TWD160401S (zh) 瓶子之部分
WO2014039513A3 (fr) Inhibition de la diacylglycérol kinase pour augmenter le transfert de lymphocyte t adoptif
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
GB0711327D0 (en) Diagnostic method
MA38925A1 (fr) Dérivés de phénylalanine substitués
PH12014502798A1 (en) Nalmefene for reduction of alcohol consumption in specific target populations
MA54889A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
FR3007655B1 (fr) Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
BR112015024516A2 (pt) métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação
EA201990799A1 (ru) Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
朱琳 Expression of Sema4D in patients with cerebral infarction and its clinical significance
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии
AU334566S (en) Visor for sunglasses and or spectacles
TR201206516U (tr) Eşya taşıyıcı hazneli bir bardak tutucu.
MX2015005305A (es) Metodos y sistemas para determinar el uso y contenido de pymk con base en un modelo de valor.